Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo

A Schäfer, F Muecksch, JCC Lorenzi, SR Leist… - Journal of Experimental …, 2020 - rupress.org
SARS-CoV-2, the causative agent of COVID-19, has been responsible for over 42 million
infections and 1 million deaths since its emergence in December 2019. There are few …
被引用次数：333 相关文章
[HTML] nih.gov

[HTML][HTML] Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo

A Schäfer, F Muecksch, JCC Lorenzi… - The Journal of …, 2021 - ncbi.nlm.nih.gov
Abstract SARS-CoV-2, the causative agent of COVID-19, has been responsible for over 42
million infections and 1 million deaths since its emergence in December 2019. There are …

Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo

A Schäfer, F Muecksch, JCC Lorenzi… - Journal of …, 2020 - folia.unifr.ch
English SARS-CoV-2, the causative agent of COVID-19, has been responsible for over 42
million infections and 1 million deaths since its emergence in December 2019. There are …

Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo

A Schäfer, F Muecksch, JCC Lorenzi, SR Leist… - Journal of Experimental …, 2020 - sonar.ch
English SARS-CoV-2, the causative agent of COVID-19, has been responsible for over 42
million infections and 1 million deaths since its emergence in December 2019. There are …

Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo

A Schäfer, F Muecksch, JCC Lorenzi… - Journal of …, 2021 - cdr.lib.unc.edu
Abstract SARS-CoV-2, the causative agent of COVID-19, has been responsible for over 42
million infections and 1 million deaths since its emergence in December 2019. There are …

Antibody potency, effector function and combinations in protection from SARS-CoV-2 infection in vivo

A Schäfer, F Muecksch, JCC Lorenzi, SR Leist… - bioRxiv, 2020 - biorxiv.org
Abstract SARS-CoV-2, the causative agent of COVID-19, is responsible for over 24 million
infections and 800,000 deaths since its emergence in December 2019. There are few …

Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo

A Schäfer, F Muecksch, JCC Lorenzi, SR Leist… - Journal of Experimental …, 2020 - cir.nii.ac.jp
抄録< jats: p> SARS-CoV-2, the causative agent of COVID-19, has been responsible for over
42 million infections and 1 million deaths since its emergence in December 2019. There are …

Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo

A Schäfer, F Muecksch, JCC Lorenzi, SR Leist… - Journal of Experimental …, 2021 - rupress.org
Disclosures: RS Baric worked with Eli Lilly to develop antibodies for the treatment of COVID-
19. DF Robbiani reported a patent to coronavirus antibodies pending. MC Nussenzweig …
[PDF] scienceopen.com

[PDF][PDF] Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo

A Schäfer, F Muecksch, JCC Lorenzi, SR Leist… - J. Exp …, 2020 - scienceopen.com
SARS-CoV-2, the causative agent of COVID-19, has been responsible for over 42 million
infections and 1 million deaths since its emergence in December 2019. There are few …

Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo.

A Schäfer, F Muecksch, JCC Lorenzi… - The Journal of …, 2021 - europepmc.org
Abstract SARS-CoV-2, the causative agent of COVID-19, has been responsible for over 42
million infections and 1 million deaths since its emergence in December 2019. There are …